{"contentid": 487962, "importid": NaN, "name": "Rebranded Revolo Biotherapeutics showcases its plans", "introduction": "Revolo Biotherapeutics, which today rebranded itself from Immune Regulation, has outlined its mission to dramatically alter the autoimmune and allergic disease treatment landscape and the culmination of significant changes made over the past year, including:", "content": "<p>Revolo Biotherapeutics, which today rebranded itself from Immune Regulation, has outlined its mission to dramatically alter the autoimmune and allergic disease treatment landscape and the culmination of significant changes made over the past year, including:</p>\n<ul>\n<li>Hiring new executives internationally at every level, including CEO Jonathan Rigby;</li>\n<li>Building a significant presence in the USA including a new headquarters in New Orleans;</li>\n<li>Closing a $53.4 million Series B financing and</li>\n<li>Planning for the initiation of four Phase II clinical trials in the USA and Europe in 2021.</li>\n</ul>\n<p>The new brand better reflects the company&rsquo;s revolutionary approach to developing therapies that reset the immune system with the goal of achieving superior long-term disease remission for patients with autoimmune and allergic diseases. Revolo Bio&rsquo;s drug candidates, &lsquo;1805 and &lsquo;1104, have already demonstrated efficacy and safety in both pre-clinical and human studies while preventing the unwanted effects of chronic immune suppression.</p>\n<p>Revolo Bio will advance &lsquo;1805 through two Phase II trials for patients with moderate-to-severe rheumatoid arthritis and for patients with non-infectious uveitis. Additionally, Revolo Bio is advancing a Phase II trial of &lsquo;1104 for patients with eosinophilic esophagitis (EoE) and a Phase II allergen sensitivity study. In addition, Revolo Bio recently initiated an additional Phase I study of &lsquo;1104 designed to evaluate the safety of ascending doses in healthy volunteers to support future Phase II clinical trials.&nbsp;</p>\n<p>&ldquo;Revolo Biotherapeutics reflects our focused mission to reset the immune system to achieve long-term disease remission of autoimmune and allergic disease,&rdquo; said Jonathan Rigby, group chief executive of Revolo Biotherapeutics.</p>\n<p>&ldquo;We are advancing four Phase II clinical programs with multiple near-term readouts occurring, and we believe that the unique, disease-agnostic mechanisms of action of our drug candidates creates vast optionality across multiple indications. Our team of successful industry professionals and immunology and allergic disease experts is rapidly growing to include more dedicated revolutionizers ready to support our upcoming milestones,&rdquo; he added.</p>\n<p>&nbsp;</p>", "date": "2021-03-05 15:45:00", "meta_title": "Rebranded Revolo Biotherapeutics showcases its plans", "meta_keywords": "Revolo Biotherapeutics, Rebranding, Phase II, Initiation", "meta_description": "Rebranded Revolo Biotherapeutics showcases its plans", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-05 15:39:56", "updated": "2021-03-05 17:40:01", "access": NaN, "url": "https://www.thepharmaletter.com/article/rebranded-revolo-biotherapeutics-showcases-its-plans", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "revolo_big.jpg", "image2id": "revolo_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Autoimmune Disorders", "topic_tag": "Companies, mergers and acquisitions, Management, Research", "geography_tag": "USA", "company_tag": "Immune Regulation, Revolo Biotherapeutics", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-05 15:45:00"}